{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:09:45Z","timestamp":1773281385178,"version":"3.50.1"},"reference-count":11,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1136\/bjophthalmol-2014-306002","type":"journal-article","created":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T10:07:18Z","timestamp":1415354838000},"page":"618-623","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD"],"prefix":"10.1136","volume":"99","author":[{"given":"Jennifer I","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Niec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vernon","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,11,6]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2014-306002-1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2014-306002-2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/138945011794182746","article-title":"Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration","volume":"12","author":"Becerra","year":"2011","journal-title":"Curr Drug Targets"},{"key":"key-10.1136\/bjophthalmol-2014-306002-3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/jop.2012.0173","article-title":"Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors","volume":"29","author":"Veritti","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2014-306002-4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/14656566.2013.787410","article-title":"An update on the pharmacotherapy of neovascular age-related macular degeneration","volume":"14","author":"Freund","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.1136\/bjophthalmol-2014-306002-5","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/archopht.1985.01050100143037","article-title":"Clearance of triamcinolone from vitreous","volume":"103","author":"Scholes","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-306002-6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00006982-200507000-00002","article-title":"Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes","volume":"25","author":"Chin","year":"2005","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-306002-7","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ophtha.2010.12.029","article-title":"Sustained-release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular edema in retinal vein occlusion","volume":"118","author":"Lim","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-306002-8","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-306002-9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-306002-10","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00492284?term=RADICAL+study&rank=3"},{"key":"key-10.1136\/bjophthalmol-2014-306002-11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.ophtha.2012.01.014","article-title":"Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE Study: Twelve month safety and efficacy results","volume":"119","author":"Dugel","year":"2012","journal-title":"Ophthalmology"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2014-306002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T23:47:32Z","timestamp":1689637652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2014-306002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,6]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,4,17]]},"published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1136\/bjophthalmol-2014-306002"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306002","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,6]]}}}